COMMUNIQUÉS West-GlobeNewswire

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/04/2026
SAN MATEO, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
06/04/2026
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, [...]
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
06/04/2026
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
06/04/2026
- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment - - Strategic financing to accelerate development of earlier-stage gene therapy [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application
06/04/2026
NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory review. NRx [...]
Sharps Technology Reports 2025 Year-End Results and Highlights Continued Execution of Solana Treasury Strategy
06/04/2026
Over 2 Million SOL Held with Approximately 95% Staked at ~7% Gross Annualized Yield Total Assets of $269.1 Million, Up from $7.3 Million at Year-End 2024 Expanded Solana Ecosystem Partnerships Including Coinbase, Crypto [...]
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference
06/04/2026
WATERTOWN, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
06/04/2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” [...]
Beacon Biosignals Upsizes Series B Financing to Over $97 Million
06/04/2026
BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Beacon Biosignals today announced an extension to its Series B financing, bringing the funding round to $97 million and the company’s cumulative funding to over $132 million. [...]
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
06/04/2026
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06 [...]
MEDVi QUAD Claims Evaluated: Real Online Doctor-Approval ED Medication for Men's Sexual Performance
04/04/2026
4-in-1 compounded prescription erectile dysfunction treatment program details, sublingual delivery format, telehealth platform structure, FDA regulatory context, and consumer verification steps for men evaluating doctor [...]
BienRaíz Launches Premium D3 + K2 Formula for Bone Health and Heart Function
04/04/2026
NEW YORK, April 04, 2026 (GLOBE NEWSWIRE) -- As research continues to reveal the critical relationship between vitamin D3 and vitamin K2, BienRaíz—a supplement brand committed to foundational wellness through nature and [...]
VigorX Pro Claims Evaluated: The VitalPro ManForceX Supplementation Method Working for Men Worldwide
04/04/2026
A 2026 informational release covering VigorX Pro's prostate health and male vitality claims, the VitalPro ManForceX supplementation method for men over 40, ingredient research context, pricing structure, 60-day [...]
Vireo Growth Inc. Partners with Ace Ventures to Establish New York’s First Minority-owned Vertically Integrated Medical Cannabis Operator
04/04/2026
Majority ownership of Vireo Health of New York to transfer to MWBE-led Ace Ventures; partnership reinforces long-term alignment with New York’s social equity framework MINNEAPOLIS, April 03, 2026 (GLOBE NEWSWIRE) -- [...]
Overcoming Onychomycosis Claims Evaluated: Blue Heron Health News Nail Fungus Treatment Program is On Sale
03/04/2026
Blue Heron Health News Explains How Scott Davis's Overcoming Onychomycosis Gut-Health and Immune-Support Program Works, What the Digital Guide Includes, Who It May Be Designed For, and How Consumers Can Verify Current [...]
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention [...]
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
03/04/2026
BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the “Company”) (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the “Notice”) from the NYSE [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2026
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]

Pages